Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant combinations in advanced NSCLC (ARC-4)
NCT03846310Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Apr 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of etrumadenant in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Arcus Biosciences. Primary endpoints: Adverse Events at 1 year and Dose Limiting Toxicity at 21 days. Started Apr 2019; status: completed.
02
Drugs
etrumadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03846310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03846310.